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    Esmolol is the first intravenous, short-acting, titratable 
β-blocker available for use in critical care and surgical settings 
[1]. Esmolol is thought to be a “jack of all trades” among drugs 
used in anesthesia because it prevents and treats cardiovascular 
responses due to perioperative stimuli. 
    In addition to its effect on the sympathetic nervous system, 
esmolol influences core components of an anesthetic regimen, 
such as analgesia, hypnosis, and memory function [2-5]. 
    In this edition of the Korean Journal of Anesthesiology, Lee 
and Lee [6] studied 60 patients who underwent a laparoscopic 
appendectomy under total intravenous anesthesia using 
propofol and remifentanil and compared a control group with 
another group that received continuously injected esmolol 
during anesthesia. Postoperative 30 minute visual analog scale 
(VAS) scores and diclofenac sodium use for postoperative pain 
control during the first 24 hours decreased significantly in the 
esmolol group. Also, Lee and Lee [6] adjusted the infusion 
rate of remifentanil to target the bispectral index (BIS) to 40-
60, compared to the control group, and the total amount of 
remifentanil administered during approximately 57 minutes 
of anesthesia was significantly lower in the esmolol group. The 
authors attributed the decrease in postoperative pain with 
esmolol to its intrinsic analgesic effect, a decrease in hepatic 
metabolism of opioids by β-blockers to extend the analgesic 
effect, and a reduction in opioid tolerance. 
    However, there are several points that Lee and Lee [6] must 
consider. First, β-blockers, which decrease hepatic opioid 
metabolism and lengthen the analgesic effect, are limited only 
to those metabolized by the liver. For example, propranolol 
decreases its own metabolism and that of certain other drugs by 
eliciting a reduction in hepatic blood flow [7]. This could affect 
the metabolism of drugs with a large hepatic extraction ratio, 
such as fentanyl, and it would seem likely that propranolol use 
would result in prolonging the analgesic effect of fentanyl and 
also elicit a reduction in postoperative opioid consumption [2]. 
    However, although the effect of esmolol on drug metabolism 
has not yet been thoroughly investigated, unlike most β-blockers, 
which are metabolized by the liver, esmolol is metabolized 
by esterases located in the cytosol of red blood cells [8]. Thus, 
it seems unlikely that esmolol infusion would alter opioid 
pharmacokinetics. 
    Furthermore, although remifentanil is a 4-anillidopiperi-
dinemethyl μ-opioid like fentanyl, alfentanil, and sufentanil, 
it is not metabolized in the liver but completely metabolized 
by nonspecific esterases [9]. Therefore, one cannot expect 
alterations in remifentanil metabolism due to esmolol in the 
study in which Lee and Lee [6] continuously infused remifentanil. 
    Secondly, the drug used for postoperative pain control in 
the study of Lee and Lee [6] was not an opioid but diclofenac 
sodium, so what should be discussed is opioid induced 
hyperalgesia not opioid tolerance.
    Opioids provide an initial analgesic effect but then reduce 
the pain threshold to less than baseline (opioid-induced 
hyperalgesia, OIH) and increase the amount of opioid 
required to achieve the same analgesia (opioid tolerance) 
[10,11]. That is, the use of opioids may be a double-edged 
sword. OIH is characterized by different clinical features 
than tolerance. OIH represents increased sensitivity to pain, 
whereas tolerance may reflect decreased sensitivity to opioids. 
Both acute opioid tolerance and OIH seem to share some 
similar molecular mechanism, which involves the activation 
of excitatory glutamate receptors of the N-methyl-D aspartate 142 www.ekja.org
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(NMDA) system in the central nervous system [12]. However, 
many other mechanisms and systems are probably involved 
in the development of opioid tolerance [13]. Several recent 
studies have reviewed and highlighted important aspects 
of OIH [10,11]. Even brief exposure to μ-receptor agonists 
can induce long-lasting hyperalgesic effect for days, which 
is clinically significant, because large doses of intraoperative 
μ-receptor agonists increase postoperative pain and opioid 
consumption [2,10]. Although some clinical studies have failed 
to demonstrate an increase in pain scores after remifentanil 
infusion, remifentanil has been shown to increase pain and 
induce mechanical hyperalgesia after a 30 min infusion at a 
dose 0.05-0.1 μg/kg/min in volunteers [14,15]. OIH worsens 
when higher doses of opioids are infused [16], so in the study 
of Lee and Lee [6], the effects of reducing remifentanil-induced 
hyperalgesia with esmolol were observed.
    Esmolol exerts antinociceptive and anesthetic sparing 
effects in animal and human subjects [17,18]. Previous studies 
have shown that a continuous esmolol infusion decreases the 
plasma propofol minimal alveolar anesthetic concentration 
during propofol/nitrous oxide/morphine anesthesia and 
reduces inhalation anesthetic minimum alveolar concentration 
(MAC) [17,19]. In 2001, Coloma et al. [20] suggested that 
perioperative esmolol is an alternative to remifentanil for 
maintaining stable intraoperative hemodynamics. Although 
intravenously administered esmolol has peripheral analgesic 
and cardiovascular properties, it is also thought to be involved 
in pain modulation [18]. Because esmolol does not cross the 
blood-brain barrier, it may prevent the increase in the BIS 
index and decrease inhalation anesthetic MAC by blocking 
β-adrenoceptors within the brainstem and decrease neuronal 
inflow traffic into the central nervous system rather than acting 
within the brain directly [21]. 
    Furthermore, ONO 1101, a specific β-blocker, injected 
intrathecally elicits a decrease in the nociceptive behavior 
following formalin injection [22]. Thus, additional studies are 
required to better define the role of centrally administered 
esmolol in pain modulation. Administration of a sufficient dose 
of a short-acting β-blocker by a neuraxial route, for example, 
may be a potentially new treatment strategy for perioperative 
pain. 
    Davidson et al. [18] reported that esmolol shows direct 
analgesic properties in formalin-injected rats, and Hagelüken 
et al. [23] demonstrated G protein activation in isolated cell 
membranes with the use of a β-blocker. Inhibitory G protein-
coupled receptor agonists act on post-synaptic inhibition via 
G protein-coupled potassium channels or via the pre-synaptic 
inhibition of neurotransmitter release through the regulation 
of voltage-gated Ca
2+ channels; such a pathway underlies the 
antinociceptive effect of clonidine [24].
    Although more reasonable discussions are needed on the 
study of Lee and Lee [6] due to the decrease in postoperative 
VAS and usage of diclofenac sodium, this may be an interesting 
study for one who is interested in remifentanil-based anesthesia 
and the resulting OIH. This study also suggests that esmolol 
may become a friendlier drug to anesthesiologists. 
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